BCAB
NASDAQBioAtla Inc.
BioAtla Inc. (BCAB) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 5 wire items for BCAB, including 4 SEC filings and 1 press release or news item. The most recent was published Oct 30, 2026.
News · 26 weeks18+400%
2026-05-172026-11-08
Mix1190d
- SEC Filings7(64%)
- Insider3(27%)
- Other1(9%)
Activity · 52 weeks5933 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form EFFECT filed by BioAtla Inc.EFFECT - BioAtla, Inc. (0001826892) (Filer)
- SECSEC Form 424B3 filed by BioAtla Inc.424B3 - BioAtla, Inc. (0001826892) (Filer)
- SECSEC Form RW filed by BioAtla Inc.RW - BioAtla, Inc. (0001826892) (Filer)
- SECSEC Form S-1 filed by BioAtla Inc.S-1 - BioAtla, Inc. (0001826892) (Filer)
- SECSEC Form 8-K filed by BioAtla Inc.8-K - BioAtla, Inc. (0001826892) (Filer)
- SECBioAtla Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - BioAtla, Inc. (0001826892) (Filer)
- INSIDERChief Medical Officer Sievers Eric covered exercise/tax liability with 134 shares, decreasing direct ownership by 1% to 11,346 units (SEC Form 4)4 - BioAtla, Inc. (0001826892) (Issuer)
- INSIDERChief Executive Officer Short Jay M Phd covered exercise/tax liability with 259 shares, decreasing direct ownership by 0.50% to 52,035 units (SEC Form 4)4 - BioAtla, Inc. (0001826892) (Issuer)
- INSIDERChief Financial Officer Vasquez Christian covered exercise/tax liability with 71 shares, decreasing direct ownership by 0.67% to 10,476 units (SEC Form 4)4 - BioAtla, Inc. (0001826892) (Issuer)
- SECBioAtla Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - BioAtla, Inc. (0001826892) (Filer)
- SECSEC Form 10-Q filed by BioAtla Inc.10-Q - BioAtla, Inc. (0001826892) (Filer)
- SECBioAtla Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - BioAtla, Inc. (0001826892) (Filer)
- INSIDERChief Financial Officer Vasquez Christian covered exercise/tax liability with 257 shares, decreasing direct ownership by 2% to 10,347 units (SEC Form 4)4 - BioAtla, Inc. (0001826892) (Issuer)
- INSIDERChief Executive Officer Short Jay M Phd covered exercise/tax liability with 898 shares, decreasing direct ownership by 2% to 52,294 units (SEC Form 4)4 - BioAtla, Inc. (0001826892) (Issuer)
- INSIDERChief Medical Officer Sievers Eric covered exercise/tax liability with 494 shares, decreasing direct ownership by 1% to 11,840 units (SEC Form 4)4 - BioAtla, Inc. (0001826892) (Issuer)
- SECSEC Form DEFA14A filed by BioAtla Inc.DEFA14A - BioAtla, Inc. (0001826892) (Filer)
- SECSEC Form DEF 14A filed by BioAtla Inc.DEF 14A - BioAtla, Inc. (0001826892) (Filer)
- PRContext Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 PHILADELPHIA, May 18, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors, today announced the amendment of the Company's exclusive license agreement, dated September 23, 2024, with BioAtla, Inc. (NASDAQ:BCAB). The amendment removes all future milestone and royalty obligations owed by the Company for CT-202, the Company's Nectin-4 x CD3 T cel
- SECSEC Form 10-Q filed by BioAtla Inc.10-Q - BioAtla, Inc. (0001826892) (Filer)
- SECAmendment: SEC Form 10-K/A filed by BioAtla Inc.10-K/A - BioAtla, Inc. (0001826892) (Filer)
- SECBioAtla Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - BioAtla, Inc. (0001826892) (Filer)
- SECSEC Form S-8 filed by BioAtla Inc.S-8 - BioAtla, Inc. (0001826892) (Filer)
- SECBioAtla Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BioAtla, Inc. (0001826892) (Filer)
- SECSEC Form 10-K filed by BioAtla Inc.10-K - BioAtla, Inc. (0001826892) (Filer)
- PRBioAtla Announces Share ConsolidationSAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it will effect a 50-for-1 share consolidation (the "Share Consolidation") of its common stock, par value $0.0001 per share (the "Common Stock"), that is expected to become effective on April 6, 2026 at 12:01 a.m. Eastern Time (the "Effective Date"). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "BCAB" and is expected to begin trading on a split-adjusted basis when the market opens
BCAB FAQ
8 questionsWhat does BioAtla Inc. do?
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder...What is the latest news on BCAB?
In the last 30 days Quantisnow tracked 5 wire items for BCAB: 4 SEC filings and 1 press release or news item. The most recent was published on October 30, 2026.Where does BCAB stock trade?
BioAtla Inc. (BCAB) is listed on NASDAQ.What sector and industry is BCAB in?
BioAtla Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did BioAtla Inc. go public?
BioAtla Inc. (BCAB) completed its IPO in 2020.What are analysts saying about BCAB?
Across the last 8 analyst actions on BioAtla Inc., there were 0 upgrades and 3 downgrades. The most recent action was from Rodman & Renshaw: Buy with a $4.00 price target on 2026-01-13.What companies are similar to BCAB?
Notable peers in the same industry include AMGN (Amgen Inc.), EXEL (Exelixis Inc.), ARGX (argenx SE), MRNA (Moderna Inc.), RVMD (Revolution Medicines Inc.). Compare BCAB side-by-side with any of them on Quantisnow.How can I track BCAB on Quantisnow?
Quantisnow aggregates BioAtla Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BCAB to receive live email and push alerts on every new disclosure.